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Abstract
A significant proportion of colorectal adenomas, in particular those that lack an elevated growth component, con-
tinue to escape detection during endoscopic surveillance. Elevation of the activity of matrix metalloproteinases
(MMPs), a large family of zinc endopeptidases, in adenomas serves as a biomarker of early tumorigenesis. The
goal of this study was to assess the feasibility of using a newly developed near-infrared bioactivatable probe
(MMPSense 680) that reports the activity of a broad array of MMP isoforms to detect early colorectal adenomas.
Adenomatous polyposis coli (Apc)+/Min-FCCC mice that spontaneously develop multiple colorectal adenomas were
injected with MMPSense 680, and the colons were imaged in an IVIS Spectrum system ex vivo. Image analyses
were correlated with histopathologic findings for all regions of interest (ROIs). The biochemical basis of fluorescent
signal was investigated by immunohistochemical staining of MMP-7 and -9. A strong correlation (Kendall = 0.80)
was observed between a positive signal and the presence of pathologically confirmed colonic adenomas; 92.9%
of the 350 ROIs evaluated were classified correctly. The correlation between two independent observers was 0.87.
MMP-7 expression was localized to epithelial cells of adenomas and microadenomas, whereas staining of MMP-9
was found in infiltrating polymorphonuclear leukocytes within the adenomas. MMPSense 680 identifies colorectal
adenomas, both polypoid and nonpolypoid, in Apc+/Min-FCCC mice with high specificity. Use of this fluorescent
probe in combination with colonoscopy could aid in preventing colorectal neoplasias by providing new opportu-
nities for early detection and therapeutic intervention.
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Abbreviations: Apc, adenomatous polyposis coli: mutation of this tumor suppressor gene is the gatekeeping event in colorectal carcinogenesis; MMPs, matrix metalloproteinases:
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Introduction
Colorectal cancer remains the second leading cause of cancer-related
mortality in the United States. Despite increased awareness of the
benefits of early detection, the compliance of the general population
with current guidelines for endoscopic surveillance remains low
(58.5%) [1]. Unfortunately, even in subjects who adhere to these
screening recommendations, approximately 20% of colorectal neo-
plasms escape detection by standard white-light colonoscopy [2,3].
This is most problematic for small mucosal colorectal lesions and
nonpolypoid (flat) or depressed lesions that lack an elevated growth
component (approximately 15%), especially in the right part of the
colon [4]. These data confirm the critical need to develop new strat-
egies for detecting early colorectal neoplasias; techniques that may
also be used to monitor response to therapeutic intervention before
changes in gross morphology.
Matrix metalloproteinases (MMPs) are a family of structurally re-
lated zinc-dependent proteases that mediate cellular infiltration, cyto-
kine activation, cell migration, tissue damage, remodeling, and repair
[5,6]. Although MMPs likely play important roles in normal tissue
physiology in the gastrointestinal tract, enhanced expression of sev-
eral isoforms (MMP-2, -3, -7, -9, -12, and -13) has been linked to
various steps in the transformation of human nonneoplastic colorec-
tal mucosa to adenomatous polyps, invasive colorectal cancers, and
metastases [7,8]. Up-regulation of MMP-7 occurs very early in co-
lonic epithelial cells as a result of mutation of adenomatous polyposis
coli (APC ) gene. Mutation of APC is the putative “gatekeeping” event
in colorectal carcinogenesis, leading to translocation of β-catenin to
the nucleus. Overexpression of MMP-7 has been found in 85% of
colorectal adenocarcinomas [9] and associated with a poor prognosis
[10]. Elevated levels of MMP-9 have been associated with colorectal
cancer metastases [11], colorectal adenomas, and severely dysplastic
polyps [12].
Weissleder et al. [13] reported the first successful optical detection
and imaging of protease activity in vivo approximately one decade
ago. On the basis of this technology, a similar series of bioactivatable
probes that use near-infrared fluorophores as optical sensors has been
developed and commercialized recently by VisEn Medical (Woburn,
MA), providing new opportunities for detecting molecular events
that may be specific to colorectal neoplasias, both polypoid and non-
polypoid (flat) lesions. In the case of MMPSense, proteolytic cleavage
of a poly-lysine peptide linker of the copolymer probe by a wide
range of MMP isozymes leads to the release of fluorophores and
the production of a signal that can be detected in the near-infrared
range; that is, an area of low autofluorescence and low photon ab-
sorption [14].
The Apc+/Min-FCCC mouse model [15] represents an ideal preclin-
ical system in which to develop image-based protocols for the early
detection of colorectal neoplasias. Unlike the conventional strain of
multiple intestinal neoplasia (Min) mice [16], Apc+/Min-FCCC mice
spontaneously develop multiple colorectal adenomas (3.7 ± 0.3,
mean ± SEM). Apc+/Min-FCCC mice do not develop colorectal cancer.
Similar to humans, adenomas are both polypoid and nonpolypoid
(flat) in morphology. Data from this group indicate that the level
of MMP-7 transcripts is elevated more than 100-fold in colorectal
adenomas from Apc+/Min-FCCC mice compared with nonneoplastic
colonic mucosa [17].
The purpose of this study was to determine the feasibility of using
a near-infrared bioactivatable probe, MMPSense 680, which reports
the activity of a broad array of MMP isoforms to detect early colo-
rectal adenomas. Results from the present study demonstrate that
MMPSense 680 identifies colorectal adenomas, both nonpolypoid
(flat) and polypoid, in Apc+/Min-FCCC mice with high specificity.
Pathologic analyses were performed to confirm the molecular basis
for the observed signal.
Materials and Methods
Reagents
MMPSense 680 was purchased from VisEn Medical.
Animal Maintenance and Treatment
All experiments were performed using a unique strain of C57BL/
6J Min mice (Apc+/Min-FCCC) [15]. A breeding colony was estab-
lished at Fox Chase Cancer Center (FCCC) more than 10 years
ago and has been maintained for more than 40 generations. All off-
spring were genotyped for a point mutation in codon 850 of the Apc
gene according to an established protocol [18]. Male and female mice
(Apc+/Min-FCCC and wild-type controls, n = 22) enrolled in this study
were maintained in a temperature- and humidity-controlled room in
the Laboratory Animal Facility and received Teklad Global 2018 diet
(Harlan Teklad, Madison, WI) and drinking water ad libitum. All
animal protocols were approved by the Institutional Animal Care
and Use Committee at FCCC.
Image Acquisition
Before entry on study, the presence of colorectal adenomas in each
Apc+/Min-FCCC mouse was confirmed by colonoscopy using a proto-
col established previously by this group [19]. Mice bearing adenomas
were injected retro-orbitally with a single dose of MMPSense 680
(2 nmol dissolved in 150 μl of phosphate-buffered saline).
After injection, mice were killed through CO2 asphyxiation, and
the colons were excised and opened their entire length. After a rinse
with phosphate-buffered saline, each colon was placed on a plastic
ruler and imaged in an IVIS Caliper LS Spectrum (Caliper Life
Sciences, Hamilton, MA). Epifluorescent images were acquired using
the following parameters: excitation wavelength = 640 nm, detection
wavelength = 700 nm, exposure time = 5 seconds, F-stop = 2, bin-
ning = 4 (“small” setting), field of view = 13.6 cm (setting “C”). After
imaging, the entire colon was fixed overnight intact on a plastic ruler
in 10% normal buffered formalin and subsequently cut at 2-mm in-
tervals (Figure 1), with the position of each slice documented on a
hard copy of the fluorescent image that had been overlaid on the cor-
responding photographic image using standard display methods on the
IVIS Spectrum system. Each slice was then assigned a unique identifier
and placed in an individual cassette for histopathologic evaluation.
Histopathologic Evaluation
Hematoxylin and eosin–stained sections of the colon (entire length)
were histopathologically evaluated for the presence or absence of ade-
nomas by a pathologist blinded to the fluorescence and white-light
findings. Adenomas were classified as polypoid, nonpolypoid, or mi-
croscopic. Any adenoma exhibiting an elevated growth pattern, either
grossly or microscopically, was considered a polypoid lesion (Fig-
ure 2A). Nonpolypoid lesions did not have an elevated (polypoid)
growth pattern and possessed a height less than or equal to twice that
of the adjacent nonneoplastic mucosa (Figure 2B). Forty percent of
the nonpolypoid adenomas were not identifiable grossly. Microscopic
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adenomas were defined as lesions consisting of one to four crypts and
were undetectable on gross examination (Figure 2C). The largest di-
ameter of each microadenoma and nonpolypoid adenoma was deter-
mined microscopically using an ocular micrometer with the objective
at a magnification of ×10.
Scoring of Images
White-light photographic and fluorescent images acquired using
the IVIS Spectrum were transferred to a local workstation and ana-
lyzed using programs written with the MATLAB language and the
Image Processing Toolbox (MathWorks, Inc, Natick, MA). Using
the ruler in the photographic image as a guide, a set of 35 to 60 se-
quentially numbered regions of interest (ROIs) were placed on the
images with each adjusted to correspond precisely to sections cut
from the colon in preparation for paraffin embedding (Figure 1).
All images were displayed, presenting the entire range of signal con-
trast. Lesion size was measured on both white-light and fluores-
cent images with the “imtool” function provided with the MATLAB
Imaging Processing Toolbox. The number of pixels spanned by the
largest diameter of each lesion was estimated and converted to milli-
meters using the image acquisition parameters. Lesion edges were
more distinct on the fluorescent images.
Digital fluorescent images of the colons of six Apc+/Min-FCCC mice
(246 ROIs) were used as a training set to identify the pathologic basis
for the fluorescent signal, thus establishing standardized guidelines
for the routine scoring of colon specimens for fluorescent signal.
The histopathologic result for each ROI was compared with the pres-
ence or absence of fluorescent signal. Inherent variation in the back-
ground signal complicated the use of a fully quantitative approach for
correlating fluorescence intensity with the presence of lesion. ROIs
from each group were compared to gain a better understanding of the
specificity of the signal. Strong fluorescence intensity signals (yellow
hue) with a circumscribed round to oval shape and focal or punctate
localization of signal were all features that correlated with the pres-
ence of a pathologically confirmed lesion. On the basis of the knowl-
edge gained using the training set, the test set was evaluated in a
blinded manner by two independent observers.
Immunohistochemistry: MMP-7 and MMP-9
Expression of MMP-7 and 9 was detected in formalin-fixed paraffin-
embedded sections of the colon tissue. Primary antibodies used were
as follows: 1) a rat anti-humanMMP-7 (clone 338; Vanderbilt Univer-
sity) at a dilution of 1:400 incubated for 1 hour at 37°C and 2) rab-
bit anti MMP-9 (catalog no. 38898; Abcam, Cambridge, MA) at a
dilution of 1:200 incubated for 1 hour at room temperature. Tissue
sections were stained using the Ventana XT (Ventana Medical Sys-
tems, Tucson, AZ) automated stainer. Both antibodies used CC1 re-
trieval for 30 minutes. A goat anti–rabbit secondary antibody was used
for MMP-9 (EnVision Kit; Dako, Carpinteria, CA), and a goat anti–
rat secondary antibody was used for MMP-7 (Vector Laboratories,
Burlingame, CA).
Figure 1. Positioning of the excised colon on a ruler for image
analysis. Each colon was divided into ROIs (boxes) and numbered
sequentially to generate discrete areas for comparison of fluores-
cent signal and histopathology.
Figure 2. Representative photographs of colorectal lesions that develop in Apc+/Min-FCCC mice. (A) Low-power view (×40) of a polypoid
adenoma that projects above the surface of the nonneoplastic colonic mucosa compared with a nonpolypoid lesion (B). (B) Low-power
view (×40) of a nonpolypoid adenoma (blue arrows) with a height less than twice that of the adjacent normal mucosa (yellow arrows). (C)
Low-power view of a two-gland microadenoma (×100) with the boxed area displayed at a higher power (×400) in the insert. Scale bars,
100 μm.
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Statistical Methods
Colon tissues from animals in the test set were scored for fluores-
cence (positive or negative), and the results were correlated with the
presence or absence of tumor/lesion across the ROIs for each animal
and for each observer separately using the Kendall τ measure. In ad-
dition, the interobserver correlation in the IVIS scores was calculated
using the measure for each animal separately. A value of this measure
close to +1 (or −1) indicates a strong positive (or negative) correlation.
Results
A pilot experiment was performed to determine the optimal time inter-
val after injection for acquiring images of colon tumors inApc+/Min-FCCC
mice. Mice (n = 6) were injected with MMPSense 680, and the ex-
cised colons, containing a total of nine tumors, were imaged in the IVIS
Spectrum system at either 48 or 66 hours after injection. MMPSense
680 was well tolerated by all mice; no animal died or became mori-
bund between the time of injection and the scheduled euthanasia.
The fluorescent signal was detected at both time points examined,
and the signal-to-background ratio improved with time. The mean
tumor-to-background ratio in the animals killed at 48 hours was 1.37
for ROIs in the distal colon (high background area) and 2.44 for ROIs
in the midcolon (low background region). At 66 hours, the signal-to-
background ratios were 2.87 and 4.68 for high and low background
areas, respectively. A postinjection time of 66 hours yielded an op-
timal signal-to-background ratio and was selected for the acquisition
of all subsequent images. Although the signal-to-background ratio in-
creased, the levels of absolute signal declined; thus, time points beyond
66 hours were not examined.
After optimization, 16 animals were injected with MMPSense and
imaged at 66 hours after injection. Representative white-light and
fluorescent images are shown in Figure 3. Animals were randomly
divided into a “training” set (n = 6, 246 ROIs) (see Materials and
Methods for description) and a “test” set (n = 10, 350 ROIs) for
image analysis. Examination of all ROIs in the test set by an observer
who had not performed the pathologic diagnoses and was blinded to
the results led to the correct classification of 92.9% (325/350) of the
ROIs as positive or negative for adenoma. The corresponding sensi-
tivity and specificity, quantifying the detection of true positives and
the elimination of false positives, respectively, were computed to be
67% and 97%. The associated median value of the Kendall τ mea-
sure across the test animals was 0.80 (range, 0.3–1.0), indicating a
strong correlation between a positive score for signal and the presence
of pathologically confirmed colonic adenomas. The degree to which
a second independent observer (also “trained”) scored lesions simi-
larly was assessed. The interobserver correlation was computed to
be 0.87 (range, 0.69–1.0).
One hundred percent of the grossly identifiable polypoid lesions
were detected using MMPSense 680, irrespective of lesion size. The
largest diameter of the lesions ranged from 2.06 to 4.95 mm on
white-light images and from 1.91 to 5.63 mm on fluorescent images
(Table 1). The Spearman rank correlation between these two sets
of measurements was 0.91. Fifty percent (2/4) of the nonpolypoid
lesions (1.0-2.4 mm) and 25% (2/8) of the microadenomas (0.05 mm)
that were identified and measured microscopically were also detected
by the probe.
MMP-7 and -9 were selected for further evaluation as isoforms of
MMP that are representative of the epithelial and stromal compartments,
respectively. Immunostaining of pathologically confirmed colorectal
Figure 3. Images of a representative colon excised from an
Apc+/Min-FCCC mouse. Pictures represent a white-light photograph
(left panel) and fluorescent image (right panel) of the same colon.
Rectangles represent separate ROIs that were positioned on the
acquired image using functions written with the MATLAB Image
Processing Toolbox. The fluorescence intensity is represented as a
pseudocolor image (MATLAB “hot” color map) overlaid on a white-
light photographic image of the colon. A ruler is visible, showing size
increments inmillimeters. Values of absolute fluorescence efficiency,
as measured by the IVIS Spectrum, are shown on the color bar in
units of 10−5. Arrows denote pathologically confirmed adenomas.
Table 1. Size of Grossly Detectable Colorectal Adenomas.*
Mouse ROI Largest Diameter from Image (mm)
White Light Fluorescence
1 8 2.39 2.05
9 2.66 2.32
12 3.07 2.05
13 2.06 1.91
2 16 2.06 2.17
17 2.5 2.56
23 2.31 2.61
3 23-24 3.84 3.74
4 13-14 4.61 5.63
5 14 4.76 4.49
6 4-7 4.88 5.19
8-9 4.73 4.77
15-17 4.95 4.46
7 13 4.06 4.1
18 3.62 3.53
8 18-19 2.87 3.19
9 4 3.85 3.35
6 4.47 4.00
7 4.01 4.44
14 2.10 2.13
22 3.39 3.87
Mean ± SEM 3.49 ± 1.03 3.45 ± 1.14
*All adenomas (100%) were scored positive for fluorescent signal.
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adenomas for MMP-7 revealed cytoplasmic localization in the epithe-
lial (mucinous and nonmucinous) cells of all adenomas irrespective of
size (n = 6; Figure 4, A and B). Occasional endothelial cells and stromal
cells also expressed MMP-7 but with much less intensity. In contrast,
MMP-9 was expressed in polymorphonuclear leukocytes (PMNLs)
that had infiltrated the lamina propria of the adenomas (Figure 4C ).
PMNLs in areas of inflammation and rare PMNLs in nonneoplastic
mucosa also expressed MMP-9. All microadenomas (n = 3,≤4 crypts)
examined exhibited positive immunostaining for MMP-7 but did not
express MMP-9. Although the intensity of MMP-7 staining among
the microadenomas was heterogeneous (very intense to faint), the cel-
lular distribution was identical to that seen in larger adenomas.
Representative tissue samples of cases exhibiting incongruence be-
tween positive signal and the presence of neoplasia were selected for
immunohistochemical verification of signal status using antibodies spe-
cific for MMP-7 and -9 proteins. In cases lacking tumor but positive
for signal, both areas of inflammation and lymphoid nodules were
found to be present. Identified foci of inflammation that scored pos-
itive for signal exhibited strong staining for MMP-9, but not MMP-7,
in the PMNLs of the ulcer bed (Figure 4D). Lymphoid nodules that
were identified histopathologically (n = 3) and scored positive for fluo-
rescent signal were examined by immunohistochemistry. In one case,
an underlying adenoma was discovered when the block was sectioned
at an increased depth. Neither of the remaining lymphoid nodules
expressed MMP-9, and only one showed faint staining for MMP-7.
Colon lesions that were negative for signal included microadenomas
that were 0.05 to 0.4 mm in diameter and nonpolypoid adenomas that
were 0.55 to 0.8 mm in diameter.
Discussion
Recent technological advances in the area of molecular imaging have
provided unique opportunities for developing new strategies for the
early detection of cancer. Results from the present study confirm that
MMP activity is a reliable biomarker of colorectal tumor development
and demonstrate that the bioactivatable probe MMPSense 680 can
be used to detect colorectal adenomas with high accuracy (92.9%).
Localization of the probe to both polypoid and nonpolypoid lesions,
when combined with the high correlation between independent ob-
servers (0.87), provides promise for the use of MMP bioactivatable
fluorescent imaging probes for improving the current rate of endo-
scopic detection of colorectal adenomas in a clinical setting.
Although bioactivatable molecular imaging probes have not been
tested in humans to date, they possess numerous highly advantageous
characteristics over other imaging modalities. First, the probes serve
as a reporter of enzymatic activity, compared with measures of nu-
cleic acid or protein levels that do not always reflect biologic func-
tion. Second, highly sensitive bioactivatable probes should be able to
detect a very small number of precancerous or cancerous cells with
enhanced protease activity. Third, detection of a lesion is based on a
molecular “fingerprint” or “signature” and thus can occur indepen-
dent of the presence of a morphologic abnormality. Fourth, a large
surface area can be examined simultaneously for probe signal. Fifth,
as sensitive reporters of alterations in molecular signaling pathways,
bioactivatable probes provide new opportunities for guiding biopsy
and surgical procedures with enhanced precision. Last, biologic re-
sponse to therapy can be monitored in real time, well in advance
of gross changes in tumor size. In general, molecular imaging is an-
ticipated to reduce the financial burden of therapy by supporting the
early detection of lesions in individuals at high risk for cancer and by
aiding in the selection of those patients who might benefit most from
tailored therapies.
The observed high correlation between fluorescent signal and patho-
logically confirmed colorectal neoplasia is consistent with the restricted
expression of MMP-7 in neoplastic cells of the colonic epithelium.
Figure 4. Immunohistochemical staining of MMP-7 and -9 in colorectal lesions of Apc+/Min-FCCC mice. High-power views (×400) of a
large adenoma (A) and a small adenoma (B) displaying strong expression of MMP-7 in the epithelial cells (arrows) compared with non-
neoplastic mucosa. (C) High-power view (×400) of an adenoma stained with anti–MMP-9 antibodies. MMP-9 is strongly expressed in the
PMNLs in the stroma/lamina propria of the adenoma but not in the epithelial cells. (D) Expression of MMP-9 in the PMNLs of an ulcer
bed that is nonneoplastic. Scale bars, 100 μm.
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This is despite the fact that MMPSense can be cleaved by several iso-
forms of MMP. In humans, low levels of MMP-7 are expressed in
50% of colorectal adenomas [9]. Its role in the development of early
adenomas has been confirmed by preclinical studies that demonstrate
that targeted deletion of MMP-7 in Min mice causes a significant re-
duction in both the size and the multiplicity of colorectal adenomas
(60%) [20]. Similar results were obtained with mice carrying a knock-
out allele of Smad4 on the same chromatid as that of mutant Apc (cis-
Apc/Smad4). Interestingly, these combined deficiencies failed to alter
the depth of tumor invasion, the number of stromal fibroblasts, or the
levels of extracellular matrix components in the tumor, suggesting that
MMP-7 is required for tumor formation but not for invasion or fibro-
sis in tumors where SMAD4-dependent transforming growth factor β
signaling is inhibited [21]. Genetic ablation of specific MMP isoforms
in Apc+/Min mice has clearly demonstrated that, unlike MMP-2, -12,
and -19, MMP-9 is essential for the development of intestinal adeno-
mas [22]. As observed in the present study, MMP-9 expression was
localized to stromal PMNLs and not epithelial cells.
The present study represents the most comprehensive analysis of
the correlation between the activity of bioactivatable probes and the
pathologically confirmed neoplasia that has been published to date.
MMP-7 activity has been imaged previously in xenografts using pro-
teolytic beacons consisting of a FRET pair as a sensor and an inter-
nal reference fluorophore [23]. While subsequent use of this probe
in Apc+/Min mice produced promising results, only small intestinal
tumors were evaluated [24]. Two factors contributed significantly
to our ability to categorize tissues as neoplastic versus nonneoplastic
(92.9%) with high accuracy. These include the use of a training set
of animals, where both the fluorescence data and the pathologic
diagnosis of the colon tissue was known a priori, and an in-depth
characterization of the pathologic basis for the signal. Pathologic re-
views of specimens in this study revealed localization of MMP-7 to
lymphoid nodules and MMP-9 to areas of intense infiltration by
PMNLs (e.g., areas of ulceration). A thorough assessment of the un-
derlying basis of the false-positive signals will be critical to increase
the specificity of the next generation of MMP probes for the early
detection of colon tumors.
Detection was achieved uniformly for all grossly identifiable
lesions; 1.9 mm or greater in diameter. This is significantly smaller
than the smallest colon tumors that can be identified during opti-
cal colonoscopy. The microadenomas detected with the probe were
0.05 mm in diameter and would not have been identified in humans
using current white-light surveillance protocols. Whereas only two of
eight microadenomas were identified using MMPSense 680, expres-
sion of MMP-7 protein was detected by immunohistochemistry in all
microadenomas, irrespective of signal. These data suggest the need to
either improve the limits of detection of the probe or use it in com-
bination with a second imaging agent. It should also be noted that the
MMP-7 antibody used does not differentiate between the proenzyme
and the active form of the enzyme [25]. Marten et al. [26] reported the
detection of 0.05-mm intestinal adenomas using a similar cathepsin B
bioactivatable near-infrared fluorescent imaging probe. However, no
strict correlative observations between putative signal area and corre-
sponding histopathologic lesions were presented.
Future studies will focus on the use of MMPSense 680 as an ad-
junct to colonoscopy to identify neoplastic lesions based on their mo-
lecular “fingerprint” (i.e., proteolytic enzymatic activity) rather than
solely on their morphology. The detection of nonpolypoid and/or
depressed lesions in sporadic or colitis-associated neoplasia by “conven-
tional” colonoscopy is notoriously difficult. Using a small and flexible
fiber-optic probe placed through the biopsy channel of a commonly
used white-light colonoscope, in conjunction with a laser source, will
enable probe excitation at specified wavelengths and allow the detec-
tion of various types of neoplastic lesions during a normal endoscopic
examination. In the clinical realm, white-light colonoscopy enables the
visualization of colonic segments, whereas the fluorescent probes
would additionally enhance the presence of easily missed small and
nonpolypoid lesions. The capacity to detect nonpolypoid lesions using
MMPSense 680, alone or in combination with other molecular probes,
suggests its potential use as a tool to guide biopsies of such lesions. The
implications of such an augmented detection system will offer new op-
portunities for screening and could potentially provide a novel platform
for the testing of agents designed to prevent or delay neoplastic pro-
gression. It might also serve as a useful strategy for the pharmacody-
namic monitoring of targeted agents that interfere with cathepsin or
MMP function. The impact of this screening strategy on health care
costs and, most importantly, colon cancer morbidity and mortality will
require the conduct of carefully designed clinical trials.
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